← Back to patent-cliff list
Vamifeport hydrochloride
Tier C — Watch / tradeVamifeport hydrochloride
Vifor
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FPN1
Indications (approved)：血色素沉着症, Sickle cell disease, Beta thalassaemia, Thalassaemia
Regional status
US
Phase II
2021-09-20
EU
Phase II
2020-06-11
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vamifeport hydrochloride?
Approved indications include: 血色素沉着症, Sickle cell disease, Beta thalassaemia, Thalassaemia.
When does the Vamifeport hydrochloride patent expire?
No public expiry year is available for Vamifeport hydrochloride yet; this page updates once verified.
How do I get a quote for Vamifeport hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07